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Despite the recent entry into the market-place of a range of new pharmacological treatments for epilepsy, most 
patients still receive the standard antiepileptic drugs. This review considers the clinical place and practical use of 
these agents. Detailed consideration is given to carbamazepine, phenytoin, sodium valproate, phenobarbital and 
ethosuximide, with lesser emphasis on primidone, clobazam and clonazepam. Individualization of therapy, 
polypharmacy, refractory epilepsy, therapeutic drug monitoring, pregnancy, withdrawing treatment, epilepsy 
prophylaxis and referral to an epilepsy centre are also discussed. The paper concludes with a statement of 12 basic 
rules in prescribing established antiepileptic drugs. 
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INTRODUCTION 
Around 50 million people have epilepsy. The 
annual incidence varies between 20 and 70 
individuals per 100,000’ with a point prevalence 
of o.4-o.8%2. Incidence rates are highest in 
childhood, plateau from 15 to 65 years, and rise 
again in the elderly. Overall, 5% of the world’s 
population will have a seizure at some time in 
their lives. These figures exclude febrile convul- 
sions, which manifest in approximately 5% of 
children. They do, however, support a substantial 
remission rate that can occur in patients who have 
never received treatment with an antiepileptic 
drug3. There is evidence, too, that the more 
seizures a patient experiences before treatment is 
begun, the more likely the epilepsy is to prove 
refractory4. This is likely to be a consequence of 
the severity of the underlying process5. 
Seizures represent the clinical manifestation of 
a number of diverse neurological and systemic 
disorders in addition to a range of idiopathic (or 
genetic) epilepsies. A specific cause can currently 
be identified in only approximately 30% of 
patients6. The diagnosis is made from the 
description of the episodes and the clinical 
context in which they occur, supplemented on 
occasion by electronecephalography. Antiepilep- 
tic drug therapy is usually begun when the patient 
has suffered more than one unprovoked seizure 
within a year. Although the majority of treated 
patients will remain fully controlled, as many a 
30% will continue to suffer seizures in the face of 
optimal deployment of antiepileptic medication’. 
Despite the entry into the market-place of a range 
of new pharmacological treatments for epilepsy, 
most patients still receive the standard anti- 
epileptic drugs. This review considers the current 
place and practical use of these agents. 
WHEN TO TREAT 
Most patients with recurrent epileptic seizures 
will require treatment. Seizures can cause injury 
secondary to falls, excessive muscular contrac- 
tions associated with convulsive activity, and 
inappropriate automatisms. Their presence will 
prevent an individual from driving, and may 
interfere with a variety of important educational, 
vocational and social activities. In addition, 
although still somewhat controversial, there is 
growing concern that some types of seizures may 
cause brain injury, producing cognitive and 
memory problems, and promoting a propensity to 
further seizures. Finally, there is a low but 
significant mortality associated with uncontrolled 
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seizures that has been estimated at approximately 
O.l-0.3% per year’. Patients may die during a 
seizure or may be found dead unexpectedly in the 
absence of direct evidence of a seizureg. 
More controversial is the issue whether to treat 
a single seizure. This may be a consequence of 
severe sleep deprivation, vasovagal syncope, or 
drug or alcohol withdrawal. Patients suffering 
such a provoked seizure do not usually have 
epilepsy and do not need antiepileptic drug 
treatment. Patients who experience an 
unprovoked seizure, however, have a significant 
chance of developing recurrent events (ranging 
from 31 to 71% depending on other risk 
factorsloY”) and may already have epilepsy. 
Those with an underlying neurological abnor- 
mality or lesion, or who have a recognized 
syndrome such as juvenile myoclonic epilepsy, 
are at higher risk and should be treated. There is, 
in addition, growing evidence that treating a 
single unprovoked tonic-clonic seizure will pre- 
vent others”, although it is not likely to alter the 
overall progno&. 
The decision whether or not to treat a patient 
with an antiepileptic drug should be made after 
ample discussions of the risks and benefits of both 
courses of action. The best drug for the patient’s 
seizure type(s) and lifestyle should be selected 
and administered in a dose that is high enough to 
bring the circulating concentrations into a relative 
target (therapeutic) range without producing 
unacceptable side-effects. Once treatment is 
instituted, the goal should be restoration of a 
normal life by complete seizure control using a 
single medication with no or minimal side-effects. 
Common errors in treating patients include 
tolerating occasional seizures in patients who 
ought to be seizure-free, mistaking cognitive and 
sedative side-effects of drugs for unavoidable 
consequences of the epileptic disorder, and failing 
to refer patients to an epilepsy clinic in a timely 
fashion. 
tion1s-‘7. CBZ is regarded as the drug of first 
choice for partial seizures by most epilepsy 
specialists. In the USA many neurologists prefer 
to start with PHT. Some clinicians, particularly in 
Europe, choose to use VPA ahead of PHT 
because of the latter’s propensity to saturation 
kinetics and their perception of a less favourable 
side-effect profile. PB is a second-line drug in 
most cases, despite its being the least expensive 
and most widely available, because of its ten- 
dency to produce sedation and depression in 
adults and hyperactivity and aggression in chil- 
dren. Among the newer antiepileptic agents, 
lamotrigine, gabapentin, vigabatrin, oxcar- 
bazepine, felbamate, topiramate and tiagabine all 
possess useful efficacy against partial seizures”. 
Generalized seizures 
For tonic-clonic seizures, VPA, PHT and CBZ 
are all effective. VPA is regarded as the drug of 
choice for patients with tonic-clonic seizures and 
spike-wave discharges on the EEG and for other 
forms of idiopathic generalized epilepsy, particu- 
larly myoclinic jerks and absences. Ethosuximide 
(ESM) still has a limited place for generalized 
absences. Here the treatment should be aimed to 
eliminate all three per second spike-wave dis- 
charges from the EEG. For those patients in 
whom absences coexist with tonic-clonic seizures 
and/or myoclonic jerks, VPA should be pre- 
ferred. Clonazepam (CLZ) has efficacy against 
absences, myoclonic jerks and tonic-clonic sei- 
zures. Its value is acutely limited by sedation and 
by the rapid development of tolerance on chronic 
administration. Lamotrigine appears to be 
effective for all types of generalized seizures18. 
INDIVIDUAL DRUGS 
CHOICE OF DRUG 
Partial seizures 
Carbamazepine (CBZ), phenytoin (PHT), phen- 
obarbital (PB), primidone (PRM) and valproic 
acid (VPA) are all effective in reducing the 
frequency of partial seizures13-14. CBZ and PHT 
are better tolerated than PB, and especially 
PRM13. There is some evidence that CBZ may be 
more effective than VPA for this indicationr4, but 
other studies have not supported this asser- 
Substantial data have accumulated over many 
decades on the clinical pharmacokinetics of the 
established antiepileptic drugs (Table 1). Their 
indications and a guide to dosing in children and 
adults are outlined in Tables 2 and 3. These drugs 
are not without their hazards and their optimum 
use must be governed by an appreciation of their 
potential for dose-related and idiosyncratic toxi- 
city (Table 4). The clinical use of each drug will 
be considered, highlighting the practical problems 
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Table 1: Pharmacokinetics of established antiepileptic drugs 
Absorption Protein Elimination 
(bioavail- binding half-life 
ability) (% bound) (hours) 
Route(s) of 
elimination 
Comments 
24-45 (single) 
8-24 (chronic) 
IO-30 
Carba- 
mazepine 
Clobazam 
Slow absorption 
(75-85%) 
Rapid absorption 
(90-100%) 
Rapid absorption 
(SO-90%) 
Rapid absorption 
(90-95%) 
Slow absorption 
(95-100%) 
Slow absorption 
@S-90%) 
70-80 
87-90 
80-90 
0 
48-54 
Enzyme inducer 
Metabolic autoinduction 
Sedative 
Tolerance 
Sedative 
Tolerance 
More rapid clearance in 
children 
Enzyme inducer 
Sedative 
Tolerance 
Enzyme inducer 
Elimination half-life 
concentration-dependent 
Sedative 
Phenobarbital a metabolite 
Tolerance 
Enzyme inhibitor 
Concentration-dependent 
protein binding 
Hepatic metabolism 
Active metabolite 
Hepatic metabolism 
Active metabolite 
Hepatic metabolism Clonazepam 
Ethosuximide 
Phenobarbital 
30-40 
20-60 
72-144 
Hepatic metabolism 
25% excreted unchanged 
Hepatic metabolism 
25% excreted unchanged 
9-40 Saturable hepatic 
metabolism 
Phenytoin 90-93 
Primidone Rapid absorption 
(90-100%) 
20-30 4-12 
7-17 
Hepatic metabolism 
Active metabolites 
40% excreted unchanged 
Hepatic metabolism 
Active metabolites 
Sodium Rapid absorption 
valproate (100%) 
88-92 
likely to be encountered during everyday 
administration. 
absence or myoclonic seizures2’. It acts by 
preventing repetitive firing of sodium-dependent 
action potentials in depolarized neurones21 via 
use- and voltage-dependent blockade of Na+ 
channels22. CBZ should be introduced at low 
dosage (100-200 mg daily) to allow tolerance to 
develop to its central nervous system side- 
effect?. The dose can then increased in 2-4 
weekly increments to a maintenance amount that 
controls the seizure disorder. A balance must be 
achieved between speed of seizure control and 
acceptance of temporary central nervous system 
toxicity. The final dose often depends on the 
extent of autoinduction of metabolism24. 
Carbamazepine 
CBZ was synthesized by Schindler at Geigy in 
1953 in an attempt to compete with the newly 
introduced antipsychotic chlorpromazine. The 
first clinical studies in epilepsy were not carried 
out until 1963. Over the years CBZ has slowly 
gained acceptance as an important treatment for 
partial and tonic-clonic seizures”. In Europe, it is 
usually preferred over PHT. CBZ is not effective, 
and may even be deleterious, for patients with 
Table 2: Dosage guidelines for established antiepileptic drugs in children 
Drug Indications Starting 
dose bg/kg/day) 
Standard 
maintenance 
dose (mg/kg/day) 
Dosage 
interval 
Carbamazepine 
Clobazam 
Clonazepam 
Partial and generalized tonic-clonic seizures 
Partial and generalized seizures 
Myoclonic epilepsy 
Lennox-Gastaut syndrome 
Infantile spasms 
Status epilepticus 
Generalized absences 
Partial and generalized tonic-clonic seizures 
Newborn seizures 
Status epilepticus 
Partial and generalized tonic-clonic seizures 
Status epilepticus 
Partial and generalized tonic-clonic seizures 
Partial seizures and generalized epilepsies 
5 10-25 bid-qid 
0.25 0.5-l od-bid 
0.025 0.025-0.1 bid-tid 
10 15-30 od-bid 
4 4-8 od-bid 
Ethosuximide 
Phenobarbital 
5 5-15 od-bid Phenytoin 
Primidone 
Sodium 
10 20-30 od-bid 
10 15-40 od-tid 
valproate 
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Table 3: Dosage guidelines for established antiepileptic drugs in adolescents and adults 
Drugs Indications Starting Commonest 
dose daily dose 
(w) bg) 
Standard 
maintenance 
dose 
(mg) 
Dosage 
interval 
Carbamazepine 
Clobazam 
Clonazepam 
Ethosuximide 
Phenobarbital 
Phenytoin 
Primidone 
Sodium 
valproate 
Partial and generalized tonic-clonic 
seizures 
Partial and generalized seizures 
Myoclonic and generalized tonic- 
clonic seizures 
Absence seizures 
Partial and generalized tonic-clonic, 
myoclonic, clonic and tonic seizures 
Status epilepticus 
Partial and generalized tonic-clonic 
seizures 
Status epilepticus 
Partial and generalized tonic-clonic 
seizures 
AI1 generalized seizures 
Partial seizures 
200 600 
10 20 
1 4 
500 1000 
60 120 
200 300 
250 300 
500 1000 
400-2000 od-qid 
10-40 od-bid 
2-8 od-bid 
500-2000 od-bid 
60-240 od-bid 
100-700 od-bid 
250-1500 
500-3000 
od-bid 
od-bid 
Some patients are unable to tolerate the 
neurotoxic side-effects of CBZ even at low 
dosage and concentration. Diplopia, headache, 
dizziness, nausea and vomiting are the com- 
monest complaints. A contribution to these 
side-effects is likely to come from the active 
metabolite CBZ 10,ll epoxide25. These symp- 
toms provide a ceiling to dosage for many 
patients with refractory epilepsy. In addition, 
high peak plasma concentrations often result in 
intermittent side-effects around 2 hours after 
dosing, necessitating three or four times daily 
administration in some patients. Such problems 
can be overcome by prescribing a controlled- 
release formulation, now available widely, 
which can be given once26 or twice*’ daily in all 
patients. 
CBZ can cause a range of idiosyncratic 
reactions, the most common of which is a 
morbilliform rash in around 10% of patients”. 
Slow dosage titration may reduce this figure*‘. 
Other unusual, but more severe, skin eruptions 
include erythema multiforme and Stevens- 
Johnson syndrome. Reversible, mild leukopenia 
often occurs, but does not require discontinuation 
of therapy unless accompanied by evidence of 
infection or if the white cell count slips below 
1 X 109/1. Blood dyscrasias and toxic hepatitis are 
rarer problems. Long-term side-effects with CBZ 
are few. At high concentrations, the drug has an 
antidiuretic, hormone-like action, that can result 
in fluid retention with cardiac failure in the 
elderly. Mild hyponatremia is usually asympto- 
matic, but if the serum sodium falls below 
120mmol/l the patient may present with con- 
fusion, peripheral oedema and worsening seizure 
contr0119. Orofacial dyskinesias and cardiac ar- 
rhythmias are other occasional complications. 
As well as inducing its own metabolism, CBZ 
can accelerate the breakdown of a number of 
other lipid-soluble drugs29. The commonest inter- 
action is with the oral contraceptive pill, neces- 
sitating for most women a daily oestrogen dose of 
50 mcg or more30. Other important metabolic 
targets include VPA, ESM, corticosteroids, anti- 
coagulants, antipsychotics and cyclosporin. Drugs 
that inhibit CBZ metabolism resulting in toxicity 
include PHT, cimetidine, dextropropoxyphene, 
diltiazem, erythromycin, isoniazid, verapamil and 
viloxaxine. An important pharmacodynamic in- 
teraction takes place with lamotrigine, resulting 
in headache, nausea, dizziness, diplopia and 
ataxia which responds to a reduction in the dose 
of either drug3’. The less common neurotoxic 
interaction with lithium (confusion, disorienta- 
tion, drowsiness, ataxia, termor, hyperreflexia) 
is also not associated with altered drug 
concentrations3*. 
The substantial variation in any given in- 
dividual in CBZ concentrations over the course of 
the day-as much as 100% with twice-daily 
dosing-makes the interpretation of concentra- 
tion monitoring problematical. In many patients, 
the dosage can be titrated adequately on clinical 
criteria alone33. Exceptions include those in 
whom compliance is suspect and patients taking a 
cocktail of antiepileptic drugs like to interact 
mutually. 
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Table 4: Side-effects of established antieoileotic drum 
Carbamazepine Clobazam Clonazepam Ethosuximide 
*Diplopia 
*Dizziness 
*Headache 
*Nausea 
Drowsiness 
Neutropenia 
Hyponatraemia 
Hypocalcaemia 
*Fatigue 
*Drowsiness 
Dizziness 
Ataxia 
Irritability 
Aggression 
Hypersalivation 
Bronchorrhoea 
*Fatigue 
*Sedation 
*Drowsiness 
Dizziness 
Ataxia 
Irritability 
Aggression (children) 
Hyperkinesia (children) 
*Nausea 
Anorexia 
Vomiting 
Agitation 
Drowsiness 
Headache 
Lethargy 
Orofacial dyskinesia 
Cardiac arrhythmia 
Weight gain 
Muscle weakness 
Psychosis 
Hypersalivation 
Bronchorrhoea 
Psychosis 
*Morbilloform rash 
Agranulocytosis 
Aplastic anaemia 
Hepatotoxicity 
Photosensitivity 
Stevens-Johnson syndrome 
Lupus-like syndrome 
Thrombocytopenia 
Pseudolymphoma 
Teratogenicity 
Rash Rash 
Thrombocytopenia 
Rash 
Erythema multiforme 
Stevens-Johnson syndrome 
Lupus-like syndrome 
Agranulocytosis 
Aplastic anaemia 
Phenobarbital Phenytoin Primidone Sodium valproate 
*Fatigue 
*Listlessness 
*Tiredness 
*Depression 
*Insomnia (children) 
*Distractability (children) 
*Hyperkinesia (children) 
*Irritability (children) 
Aggression 
Poor memory 
Decreased libido 
Impotence 
Folate deficiency 
tNeonatal haemorrhage 
Hypocalcaemia 
Osteomalacia 
*Nystagmus 
*Ataxia 
Anorexia 
Dyspepsia 
Nausea 
Vomiting 
Aggression 
Depression 
Drowsiness 
Headache 
Paradoxical seizures 
Megoblastic anaemia 
Hyperglycaemia 
Hypocalcaemia 
Osteomalacia 
tNeonatal haemorrhage 
*Fatigue 
*Listlessness 
*Tiredness 
*Depression 
*Psychosis 
*Decreased libido 
*Impotence 
*Hyperkinesia (children) 
*Irritability (children) 
Nausea 
Vomiting 
Nystagmus 
Ataxia 
Folate deficiency 
Hypercalcaemia 
Osteomalacia 
Megoblastic anaemia 
tNeonatal haemorrhage 
*Tremor 
*Weight gain 
*Hair fall 
Anorexia 
Dyspepsia 
Nausea 
Vomiting 
Alopecia 
Peripheral oedema 
Drowsiness 
Hyperammonaemia 
Macropapular rash 
Exfoliation 
Toxic epidermal necrolysis 
Hepatotoxicity 
Frozen shoulder 
Teratogenicity 
*Acne 
*Gum hypertrophy 
*Coarse facies 
*Hirsutism 
Blood dyscrasias 
Lupus-like syndrome 
Reduced serum 1 gA 
Pseudolymphoma 
Peripheral neuropathy 
Rash 
Stevens-Johnson syndrome 
Dupuytren’s contracture 
Hepatotoxicity 
Teratogenicity 
Rash 
Agranulocytosis 
Thrombocytopenia 
Lapus-like syndrome 
Teratogenicity 
Acute pancreatitis 
Hepatotoxicity 
Thrombocytopenia 
Stupor 
Encephalopathy 
Teratogenicity 
Above line: Dose-related 
Below line: Idiosyncratic. 
* Commonest side-effects. 
t Maternal treatment. 
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Phenytoin 
The appreciation that an epileptic seizure was 
accompanied by an electrical ‘storm’ in the brain 
led Houston Merritt and Tracy Putnam to screen 
a wide of variety of phenyl compounds against 
electrically induced seizures in cats in the belief 
that this chemical grouping was responsible for 
the anticonvulsant effect of PB. This led rapidly 
to the discovery of PHT. Several mechanisms 
have been implicated in explaining its antiepilep- 
tic action, but voltage-and use-dependent 
blockade of Na’ channels appears to be the 
primary one 34 It can also reduce the amplitude of .
synaptic potentials, but at low stimulus fre- 
quencies this effect is relatively smal13’. PHT is an 
effective treatment for partial and tonic-clonic 
seizures. It is one of a handful of drugs that 
switches from first-order to saturation kinetics at 
therapeutic dosage36. Accordingly, at concentra- 
tions around 60~mol/l (15 mg/l) a moderate 
increment in dose can produce an unexpectedly 
large rise in plasma level with accompanying 
neurotoxicity. Conversely, the circulating con- 
centration can fall precipitously when the dose is 
reduced mostly, sometimes resulting in seizure 
breakthrough. The dosage, therefore, producing 
the same circulating concentration, varies greatly 
among individuals. 
A starting amount of 5 mg/kg body weight will 
produce concentrations within the target range of 
40-80 pmol/I (lo-20 mg/I) in most patients. 
Some, however, will saturate at this dose and 
present with neurotoxicity. Others will require a 
much higher dose, particularly enzyme-induced 
alcohol abusers. Below 32 pmol/l (8 mg/l), an 
increment not exceeding 100 mg can be made; 
patients with PHT concentrations above 
32 pmol/l (8 pg/ml) should receive smaller do- 
sage increments (no more than 50mg) with 
frequent monitoring. At levels nearing the upper 
limit of the target range, the dose should be 
increased by as little as 25 mg daily. Some 
patients will tolerate concentrations above 
100 pmol/l (25 mg/l) with benefit. 
PHT can produce a range of dose-related and 
idiosyncratic adverse effects (Table 4). Of the 
latter, cosmetic changes (gum hyperplasmia, 
acne, hirsutism, facial coarsening), although often 
mild, can be troublesome. Symptoms of neuro- 
toxicity (drowsiness, dysarthria, tremor, ataxia, 
cognitive difficulties) become increasingly likely 
the more the concentration exceeds 80pmol/l 
(20mg/l). Younger patients may report nausea 
and vomiting. The diagnosis of PHT toxicity 
should be made on clinical grounds and not be 
assumed from a high concentration. The patient 
will complain of mental slowing and unsteadiness, 
and neurological examination will reveal nystag- 
mus and ataxia. Heel-toe walking is particularly 
sensitive. Permanent cerebellar damage3’ may be 
a consequence of chronic toxicity, and so it is 
important to examine the patient regularly. A 
paradoxical increase in seizure frequency may 
also point the way to PHT toxicity. 
PHT is an enzyme inducer and is capable of 
accelerating the metabolism of a range of 
lipid-soluble drugs including CBZ, VPA, ESM, 
anticoagulants, steroids and cyclosporin3*. 
Because its metabolism is saturable, the drug 
provides a target for mono-oxygenase inhibitors, 
such as allopurinol, amiodarone, cimetidine, 
imipramine and some sulphonamides. Protein- 
binding displacement interactions with anti- 
epileptic drugs are only clinically relevant when 
there is concomitant enzyme inhibition, as is the 
case with PHT and VPA39. 
Valproic acid 
The anticonvulsant properties of VPA were 
recognized serendipitously in 1963, when it was 
used by Pierre Eymard as a solvent for a number 
of other compounds. It is now established as 
effective over the complete range of seizure types, 
with particular value in the idiopathic generalized 
epilepsies4’. VPA’s mechanism of action is poorly 
understood4’. It is currently believed to exert its 
antiepileptic effects, at least in part, by a 
mechanism similar to that of PHT and CBZ, 
limiting sustained repetitive firing by use- and 
voltage-dependent effect on Na+ channels4’. 
However, VPA has many active metabolities 
whose effects are not well characterized and, 
given its wide spectrum of antiepileptic activity, 
other cellular mechanisms are likely to be 
involved. 
The starting dose for adults and adolescents 
should be 500mg daily for 1 or 2 weeks, 
increasing in most patients to 500 mg twice daily. 
Alterations thereafter can be made according to 
the clinical status of the patient. Many patients 
will need to take 1500-2000 mg daily. Since the 
drug can take several weeks to become fully 
effective, frequent dosage adjustments shortly 
after initiating therapy are unwarranted. Because 
VPA does not exhibit a clear-cut concentration 
effect-toxicity relationship and daily variations in 
concentration at a given dose are wide, routine 
monitoring may not be helpful unless correlated 
with the patient’s clinica situation. In addition, 
patients frequently need and tolerate concentra- 
tions up to 1040 pmolll (150 mg/l). 
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Common unpleasant side-effects with VPA are 
dose-related tremor, weight gain, thinning or loss 
of hair (usually temporary), and menstrual 
irregularities including amenorrhea. There is 
some evidence implicating its use in the produc- 
tion of polycystic ovariesJ3. Sedation is an 
uncommon complaint although stupor and en- 
cephalopathy can occur, possibly as a conse- 
quence of underlying carnitine deficiency”. 
Hepatoxicity, histologically a microvesicular 
steatosis similar to that found in Reye’s syn- 
drome, affects fewer than one in 20,000 treated 
individuals. This appears to be a particular worry 
in children under 3 years-of-age receiving anti- 
epileptic polypharmacy, some of whom will have 
a co-existent metabolic defect45. Hyperam- 
monemia without hepatic damage can be dem- 
onstrated in approximately 20% of all patients 
receiving VPA46. This is usually transient, but 
occasionally can present clinically with confusion, 
nausea and vomiting, and clouding of conscious- 
ness. Other sporadic problems include throm- 
bocytopenia and pancreatitis. 
VPA can inhibit a range of hepatic metabolic 
processes, including oxidation, conjugation and 
epoxidation4’. Targets include other antiepileptic 
drugs, particularly PHT, PB, CBZ epoxide and 
lamotrigine31. Aspirin displaces VPA from its 
binding sites on plasma proteins and inhibits its 
metabolism4’. VPA does not interfere with the 
hormonal components of the oral contraceptive 
pill. 
Phenobarbital 
The discovery of the antiepileptic properties of 
PB was another classic example of serendipity. A 
German physician, Alfred Hauptmann, had been 
assigned rooms over his ward of patients with 
epilepsy. Unable to get a night of uninterrupted 
sleep, he provided them with a blanket prescrip- 
tion of PB as an hypnotic. To his surprise and 
delight, this treatment reduced the number of 
seizures during the night and throughout the day. 
PB is used worldwide and recent trials have 
confirmed it to be as effective as CBZ and PHT in 
abolishing partial and generalized tonic-clonic 
seizures13. The anticonvulsant effects of PB are 
believed to be mediated through potentiation of 
gamma aminobutyric acid (GABA) inhibition by 
binding to a specific site on the GABA* receptor 
chloride channel complex. At a cellular level, PB 
produces a prolongation of inhibitory postsynap- 
tic potentials by increasing the mean chloride 
channel opening time and the duration of 
GABA-induced bursts4’. 
PB is an easy drug to use clinically. To 
minimize sedation, a low dose should be started 
(60 mg in adults, 4 mg/kg in children), which can 
be increased gradually according to clinical 
requirements. The value of measuring circulating 
PB is limited as the concentration associated with 
optimal control varies considerablJ’. In addition, 
the development of tolerance to its central 
nervous side-effects makes the toxic threshold 
imprecise. Nevertheless, an unexpectedly low or 
high concentration may help to make the correct 
clinical decision in an individual patient. 
The major problem in the clinical use of PB lies 
in its propensity to influence cognition, mood and 
behaviour. It can produce fatigue, listlessness and 
tiredness in adults and insomnia, hyperactivity 
and aggression in children (and sometimes in the 
elderly)“. Subtle impairment-of memory, mood 
and learning capacity can occur in both groups. 
Depression may be associated with long-term 
administration, and arthritic changes and 
Dupuytren’s contracture can be associated prob- 
lems. Tolerance develops to the deleterious 
cognitive effects but also, unfortunately, to its 
anticonvulsant efficacy in some patient$l. PB is 
the archetypal enzyme inducer and can accelerate 
the metabolism of a long list of lipid-soluble 
drugs5*. 
Primidone 
PRM was synthesized initially in an attempt to 
produce a non-sedative barbiturate. The first 
clinical trials in epilepsy took place in 1952. It was 
not appreciated for some time that the parent 
drug was biotransformed to PB and another 
active metabolite, phenylethylmalonamide. The 
efficacy of PRM is similar to that of PB, but it is 
less well tolerated13. Not surprisingly, withdrawal 
may result in seizure exacerbation. There is, 
therefore, little to recommend this drug over PB 
for those patients in whom treatment with a 
barbiturate is contemplated. A poor correlation 
exists between PRM concentrations and efficacy 
and toxicit$‘. The major metabolite, PB, can be 
measured if compliance is an issue. 
Ethosuximide 
ESM was the product of a successful search by 
Parke Davis for a less toxic alternative to 
trimethadione in the treatment of absence sei- 
zures. It was introduced into clinical practice in 
1958 and retains a limited place in the antiepilep- 
tic armamentarium. ESM acts by reducing low 
threshold, transient, voltage-dependent calcium 
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conductance in thalamic neurons53. Slow intro- 
duction is sensible to anticipate the development 
of gastrointestinal and central nervous system 
side-effects. In children over 6 years, 500 mg/day 
is a reasonable starting dose, with further 
increments as necessary to a maximum amount of 
l-2g daily. For most patients the dose can be 
increased every 2-4 weeks. Infants require higher 
weight-related dosing, i.e. 15-30 mg/kg daily. 
The side-effects of ESM are dose-related and 
usually involve the gastrointestinal tract (nausea, 
vomiting, abdominal pain) or central nervous 
system (lethargy, dizziness, ataxia). They do not 
readily correlate with high circulating ESM 
concentrations and are usually volunteered by the 
patient or his or her family. ESM dosage 
adjustment can be assessed clinically or oc- 
casionally electroencephalographically with tele- 
metry. Routine drug monitoring is not necessary, 
but a measurement can be helpful in distinguish- 
ing a patient who is resistant to ESM’s phar- 
macological effect from one who has low con- 
centrations as a consequence of incomplete 
compliance or rapid degradation33. ESM itself 
does not interfere with drug metabolism, but does 
provide a target for enzyme inducers such as PI-IT 
and CBZ, or inhibitors such as VPA38. 
Clobazam 
Clobazam (CLB) was introduced as an anxiolytic 
in 1975, and its anti-seizure activity was recog- 
nized soon after. It is a 1,5 benzodiazepine that 
exerts its activity by potentiating the inhibitory 
action of gamma aminobutyric acid54. CLB is a 
useful adjunctive drug in refractory epilepsy”. 
Only a minority of patients, however, achieve a 
worthwhile improvement in seizure control on 
long-term dosing due to the development of 
tolerance. Some of these will have an anatomical 
basis for their seizure disorde15. Nevertheless, a 
useful proportion (lo-20%) will become seizure- 
free”. There is some evidence that intermittent 
use of CLB reduces the likelihood of tolerance56. 
Short-term administration, e.g. 20-30 mg daily 
for 3 days, can be effective in women with 
catamenial exacerbations and as ‘cover’ for 
special events such as holidays, weddings and 
surgery. A single dose of 30mg can have a 
prophylactic effect if taken immediately after the 
fnst seizure in patients who suffer regular clusters 
of complex partial or secondary generalized 
seizures. CLB’s structure differs slightly from 
those of clonazepam and diazepam, and this may 
account for a lesser propensity to produce 
sedation. Nevertheless, depression, irritability 
and tiredness are commonly reported5’. As with 
barbiturates, deterioration in behaviour and 
mood .disturbance can occur, particularly in 
patients with learning disabilities in whom CLB 
should probably be avoided. Withdrawal seizures 
can also be a problem. 
Clonazepam 
CZP has efficacy against absences, myoclonic 
jerks and tonic-clonic seizures58. As with other 
benzodiazepines, sedation and tolerance substan- 
tially reduce its usefulness. Few patients respond 
well to this drug, and nearly 50% will have an 
exacerbation of their epilepsy when it is 
withdrawn5’. Accordingly, it now has a narrow 
role in the modem management of epilepsy, 
possibly limited to refractory myoclonic seizures. 
Like other benzodiazepines, CZP should only be 
prescribed as a last resort for patients with 
learning difficulties. 
lNDlVlDUALlZATlON OF THERAPY 
The choice of drug for the individual patient 
depends on the seizure type or types and the 
likely tolerability to potential side-effects. 
Another important factor is the prescribing 
clinician’s experience. For most patients with 
partial and tonic-clonic seizures, CBZ is a good 
first choice. Some individuals have early problems 
with rash or central nervous system toxicity. If, 
because of intermittent side-effects, the drug 
needs to be administered more than twice daily, 
compliance can become an issue. In such circum- 
stances a controlled-release formulation should 
be substituted. CBZ induces the metabolism of 
the hormonal components of the oral contracep- 
tive, and this may cause difficulty in ensuring 
adequate protection against unwanted pregnancy. 
Its enzyme-inducing properties can be a major 
drawback in patients receiving other lipid-soluble 
drugs such as warfarin, cyclosporin, etc. The 
association of CBZ with neural tube defects 
should also be kept in mind when prescribing the 
drug in female patients of child-bearing 
potentialm. 
PHT is as effective as CBZ against partial and 
tonic-clonic seizures. It can be administered once 
or twice daily and a useful parenteral preparation 
is available. Gum hypertrophy, hirsutism and 
changes in facial features are unpredictable 
side-effects. Advice on mouth hygiene can pre- 
vent the first of those, and the latter two are often 
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mild and can be reversible. Teratogenesis is a 
potential problem in this patient population, as is 
PHT’s induction effect on the oral contraceptive 
pill and other lipid soluble drugs. Saturation 
kinetics make PI-IT a poor choice for patients 
whose compliance is likely to be erratic. It is 
usually necessary to monitor its circulating 
concentration. 
VPA is particularly effective for the idiopathic 
generalized epilepsies, although it also has 
efficacy against localization-related tonic-clonic 
and partial seizures. Its tendency to cause weight 
gain and patchy hair loss can cause problems, 
although many patients tolerate the drug well. 
Teratogenesis, particularly neural tube defects, is 
undoubtedly a worq@ as is its reported effect in 
producing polycystic ovaries43. These can be a 
particular concern to young women with 
idiopathic generalized seizures, in whom there is 
. an expanding place for lamotrigine31. Care should 
be taken when prescribing VPA for infants and 
young children with suspected inborn errors of 
metabolism because of the particular risk of 
hepatotoxicity. 
PB, which is as effective as CBZ and PI-IT 
against partial seizures, is usually reserved for 
patients intolerant to these agents, as it is sedative 
and can produce depression. PB is an unattractive 
alternative for children, because of its deleterious 
influence on learning and behaviour. In addition, 
it is the archetypal enzyme inducer and acceler- 
ates the metabolism of a range of other lipid- 
soluble drugs. On the positive side, PB is 
inexpensive and easy to use. Accordingly, it still 
has an important role to play in the management 
of epilepsy in the third world, where cost is the 
overwhelming consideration in the choice of 
therapy. 
POLYPHARMACY 
More than 25% of people with epilepsy appear 
refractory to optimal therapy with a single 
antiepileptic drug. Many of these will have partial 
seizures secondary to an underlying anatomical 
abnormality. The temptation is to add other drugs 
until acceptable improvement occurs. Current 
evidence suggests, however, that this strategy will 
be successful in only around 10% of such 
patients . 62 It is likely that combining established 
drugs with similar, multiple and overlapping 
modes of action is responsible for this disappoint- 
ing outcome. Recent placebo-controlled studies 
with newer agents, some of which have specific 
mechanisms of action, hold out the possibility of 
more promising combination therapy for refrac- 
tory partial seizures’*. 
Combining antiepileptic drugs results in a 
number of deleterious adverse interactions 
largely involving hepatic metabolic processes. No 
fewer than four of the established drugs, CBZ, 
PHT, PB and PRM (metabolized in part to PB) 
have the ability to induce the synthesis of 
oxidative and conjugating enzymes3g. All will 
accelerate the breakdown of VPA, ESM and 
CZP. When given together, mutual enzyme 
induction is often the result. The exception 
appears to be with CBZ and PHT. When 
combined, PHT induces CBZ metabolism, 
whereas CBZ, paradoxically, reduces the clear- 
ance of PHp3. The result is a rise in PHT 
concentration accompanied by a fall in that of 
CBZ. Interactions with CBZ can be complicated 
by an increase in the concentration of the active 
metabolite, CBZ lo,11 epoxide, which occurs 
during dual therapy with enzyme-inducing anti- 
epileptic drugs and with the inhibitor VPAU. 
VPA also inhibits PHT, PB and lamotrigine 
metabolism65. The extent of the metabolic inter- 
actions between antiepileptic drugs varies sub- 
stantially among patients. With many, there will 
be no clinical repercussions. Others will suffer a 
major alteration in circulating concentration 
resulting in seizure exacerbation or neurotoxicity. 
Measuring the total drug concentration will often 
help with appropriate dosage adjustment@. It is 
important, too, that discontinuing an enzyme- 
inducing or inhibiting drug may have a substantial 
influence on the concentration of the remaining 
agent@‘. 
It has been known for some time that 
antiepileptic drugs in combination can impair 
cognition68. This may, in part, be due to the 
severity of the underlying seizure disorder, 
particularly in the presence of brain pathology6’. 
However, the weight of evidence strongly sup- 
ports an additive effect with established anti- 
epileptic drugs and has contributed to the strong 
pressure toward monotherapy”. A multifactorial 
situation involving seizure severity, anatomical 
disease, and kinetic and dynamic drug interac- 
tions offers the most plausible explanation for this 
phenomenon. Antiepileptic polypharmacy is also 
more likely to result in teratogenesis and this will 
be discussed later. 
REFRACTORY EPILEPSY 
As many as 20% of patients referred to a 
specialist service with refractory seizures will not 
have epilepsy at all. Most of these will have 
168 M.J. Brodie & MA. Dichter 
pseudoseizures71. Clues to this diagnosis include 
wide variation in the clinical presentation of the 
events, aggressive behaviour during the episodes, 
normal or non-specific electroencephalographic 
changes, and worsening of seizure control on 
adding a small dose of an antiepileptic drug. 
Some of these patients will be young women, who 
have been sexually abused’*. Other patients do 
have epilepsy, but will be receiving inappropriate 
treatment, in particular CBZ or PHT for syn- 
dromes involving myoclonic jerks. A few will 
have absences treated with drugs other than VPA 
or ESM. Some will have an indolent glioma. 
Erratic compliance or covert alcoholism or drug 
abuse are other reasons for apparent 
‘refractoriness’. 
Before treating a patient with more than one 
antiepileptic drug, all reasonable monotherapy 
options should be exhausted. This may consist of 
just one first-line drug tolerated at high dosage in 
some circumstances, e.g. if there is an underlying 
resectable lesion. An alternative drug should be 
introduced slowly. If successful, the original drug 
can often be withdrawn, although not in all 
patients . 73 If seizure control remains poor at the 
highest tolerated dose of a second first-line drug, 
it is time to try dual therapy. There are no 
controlled clinical trials to tell us what are the 
best drugs to combine. For partial and general- 
ized seizures, many specialists employ two of the 
three first-line agents, namely CBZ, VPA and 
PHT, although their mechanisms of action are 
complex and overlapping. A more logical ap- 
proach may be to add one of the newer 
antiepileptic drugs with a different mechanism of 
action. For myoclonic seizures not responding to 
VPA, lamotrigine or a benzodiazepine such as 
CZP can be added, while intractable typical or 
atypical absences may respond to VPA and 
ESM74 or lamotrigine75 in combination. It would 
be counter-productive to introduce a sedative 
drug such as PB or PI&l at this stage, since, if this 
strategy is ineffective, subsequent withdrawal of 
the barbiturate will almost certainly produce 
withdrawal seizures. If the problem is refractory 
partial seizures, the addition of one of the newer 
drugs-lamotrigine, vigabatrin, gabapentin, ox- 
carbazepine, topiramate or tiagabine-may be 
more appropriate”. There is mounting evidence 
to suggest that VPA and lamotrigine in combina- 
tion may be particularly effective for a number of 
seizure types3’,“. 
In some patients truly refractory to phar- 
macotherapy, the law of diminishing returns will 
require patient and doctor to accept the persis- 
tence of some seizures. In such a situation, it is 
important to balance adequacy of control with 
optimal quality of life. If seizures continue despite 
treatment with multiple antiepileptic drugs, little 
can be lost in many patients by gradually reducing 
the number of drugs and simplifying the dosage 
schedules. This manoeuvre will often, paradoxi- 
cally, reduce seizure frequency76. Unfortunately, 
in a few patients seizure frequency may dramati- 
cally worsen or tonic-clonic seizures emerge. 
Slow reduction will avoid the likelihood of status 
epilepticus. Producing less intrusive episodes, 
abolishing tonic-clonic seizures, preventing falls, 
and decreasing automatisms can all be acceptable 
end-points in patients with difficult epilepsy. 
Other important options include early work-up 
for epilepsy surgery or trying a range of new 
antiepileptic drugs. This latter alternative is 
unlikely to be successful if the patient is already 
taking high doses of three antiepileptic drugs! 
THERAPEUTIC DRUG MONITORING 
Although monitoring antiepileptic drug con- 
centrations can be helpful in optimizing the dose 
in some patients, rigorous adherence to a narrow 
concentration range is likely to result in the 
doctor treating the drug level and not the 
patient”. The ‘therapeutic’ or, better, ‘target’ 
range can only be regarded as an approximation, 
based as it is on population data. Some patients 
will do well with levels below the lower limit of 
the target’*, whereas other require concentrations 
above the range to become seizure-free79. All too 
often the dose is reduced because of a reported 
‘toxic’ level, when the patient is symptom- and 
seizure-free. In other patients who are not fully 
controlled, the dose may not be increased 
appropriately for fear of stepping outside a 
mythical ‘therapeutic’ range. 
Nevertheless, appropriate use of concentration 
monitoring, particularly on site at an epilepsy 
clinic, can promote an improved outcomexO. Once 
treatment is initiated, the goal is complete seizure 
control using a single drug with no or minimal 
side-effects. It makes sense, therefore, to ensure 
that the concentration in a patient with newly 
diagnosed epilepsy, who may well have infre- 
quent seizures, is within the relevant target range 
to optimize the likelihood of perfect control. 
Levels are useful also in encouraging compliance. 
Monitoring can be helpful in a well-controlled 
patient with a break through seizure. A lower 
than expected concentration may indicate a 
change in metabolism (e.g. CBZ inducing its own 
metabolism), may reflect an unexpected interac- 
tion with another drug, or may suggest a lapse in 
compliance, a particular problem in adolescents. 
Levels can distinguish between too much 
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medication and too little. For example, some 
patients with partial seizures complain of memory 
difficulties. This can result from the pathology 
underlying the seizure disorder, from the seizures 
themselves, from subclinical ictal discharges, or 
from a deleterious effect of medication. A 
concentration measurement can determine 
whether or not a new symptom is likely to 
represent a side-effect of treatment. Monitoring 
can also be useful in circumstances where 
concentrations vary unexpectedly or unpredic- 
tably. For a drug like PHT, which undergoes 
saturation kinetics, neurotoxic symptoms may 
occur after a small increment in dose. Concentra- 
tions may be altered by co-administered medica- 
tions (especially enzyme inducers and inhibitors), 
during pregnancy, in patients with renal or 
hepatic impairment, or when other medical 
conditions, e.g. thyroid disorders, co-exist. 
Although therapeutic drug monitoring can facilit- 
ate patient management, its major limitations 
must also be appreciated”. Drug concentrations 
vary widely over the course of a day and so 
monitoring is best related to the time since 
dosing. Another potential pitfall is the presence 
of active metabolites (e.g. with VPA or CBZ). 
Certian drug interactions will lower the parent 
drug level, while elevating that of a potentially 
toxic metabolite. 
Finally, the therapeutic and unwanted effects of 
antiepileptic drugs may occasionally be reflected 
better by free than by total concentrationss2. In 
most circumstances, these will correlate well. This 
is not the case, however, when protein-binding is 
reduced. Such situations occur in the neonate, in 
old age, in pregnancy, in severe renal and hepatic 
impairment, and with the co-prescription of drugs 
that can alter binding. The methodology for 
measuring free levels is more complex, less 
reliable, and more expensive than assaying total 
drug concentrations. However, when a patient 
experiences an unexpected degree of toxicity at 
apparently modest or moderate dosage, measure- 
ment of the free level may indicate the cause. 
PREGNANCY 
Most women with treated epilepsy undergo 
uneventful pregnancies and deliver healthy 
babiess3. During pregnancy, however, metabolic 
and excitatory processes change and closer 
attention should be given to antiepileptic drug 
concentrations. Total levels of some established 
drugs will fall, particularly those of PHP. 
Women who are well controlled will usually 
remain so during pregnancy and delivery. How- 
ever, those who continue to report seizures may 
suffer a deterioration. There is a small increased 
incidence of significant fetal malformations in the 
offspring of epileptic women, even if they are 
untreated&. Commonly quoted figures are 2% in 
the general population compared with 3% for 
women with epilepsy. The risk increases with the 
number of antiepileptic drugs, being approxim- 
ately 3% for one drug (similar to background), 
5% for two, 10% for three, and over 20% in 
women taking as many as four antiepileptic 
drugs . 86 The mechanism is likely to involve the 
production of mutagenic metabolitess7. 
A syndrome consisting of facial dimorphism, 
cleft lip and palate, cardiac defects, digital 
hypoplasia and nail dysplasia has been identified. 
This was initially ascribed to hydantoins including 
PHT (‘fetal-hydantoin syndrome’), but is now 
known to occur with most other antiepileptic 
drugs, including CBZ and VPAs7. There are no 
clear data indicating differences in safety among 
PHT, PB or PRM. Current evidence suggests, 
however, that VPA and CBZ are associated with 
a low incidence of neural tube defects, probably 
l-2% and OS-l%, respectively88. 
Although it would be ideal for a woman 
contemplating pregnancy to have her antiepilep- 
tic medication withdrawn, for many this would 
result in recurrence or exacerbation of seizures, 
which could be dangerous for both mother and 
baby. If the criteria for discontinuation of 
medication are met, this should be done over a 
suitable interval before conception. Other pati- 
ents should be tapered to a minimal effective dose 
of, if possible, a single antiepileptic drug. In 
addition, supplemental folic acid should be 
administered preconceptually in an attempt at 
preventing neural tube defects. To be effective, 
folate must be taken during the first 5 weeks of 
gestation. The current recommendations are 
5 mg/day folic acid for women who have had a 
child with such a defect, and 0.4 mg daily in other 
women planning a pregnancy”. It seems sensible, 
however, to recommend the full 5 mg folate daily 
for all women receiving treatment with anti- 
epileptic drugs=. 
Eznyme-inducing antiepileptic drugs (CBZ, 
PHT, PB and PRM) can cause transient and 
reversible deficiency in vitamin K-dependent 
clotting factors in the neonate. Following a 
traumatic birth, there is an increased risk of 
intracerebral hemorrhage. Accordingly, pregnant 
women receiving one or more of these drugs 
should be treated with 20 mg of vitamin K1 daily 
during the last month of pregnancy, and babies at 
risk should receive a single intramuscular dose of 
1 mg of vitamin K, immediately after birthgO. 
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WITHDRAWING TREATMENT 
A successful outcome for treated epilepsy can be 
regarded as a patient who becomes seizure-free in 
the absence of, adverse effects. Such individuals 
usually lead integrated lives, with successful 
intellectual and emotional development and 
positive educational and vocational achieve- 
ments. Indeed, many such patients can eventually 
have their medication withdrawn and will remain 
seizure-free”. Patients who are ‘doing well’ may 
want to stop treatment for a variety of reasons, 
including the presence of unpleasant side-effects 
or the subjective perception of subtle deteriora- 
tion in cognitive function. In addition, taking 
medication does not equate with normal health. If 
drug therapy is stopped and seizures do not recur, 
there is a sense of being ‘cured’ of the stigma of 
epilepsy. Finally, patients may want to become 
parents and are often concerned about the 
possible negative effects of antiepileptic drugs on 
reproductive function and about the spectre of 
teratogenesis. Several studies have shown that 
after a period of optimal seizure control, medica- 
tion can be stopped without recurrence (at least 
within several years) in more than 60% of 
patients92-96. 
There are no data to indicate an optimum 
length for the seizure-free period; most studies 
used 2-5 years9’. Seizure type or epilepsy 
syndrome is not absolutely predictive of recur- 
rence. However, a few specific childhood syn- 
dromes, such as benign epilepsy of childhood with 
rolandic spikes and benign familial neonatal 
convulsions, tend to do well after drug with- 
drawal, whereas juvenile myoclonic epilepsy 
conveys a high probability of relapse. Some forms 
of idiopathic generalized seizures, either absence 
or tonic-clonic, if existing alone, are less likely to 
recur after control is achieved. However, even 
complex partial seizures can disappear after a 
long period of perfect control. 
Individuals with the highest probability of 
remaining seizure-free after medication is discon- 
tinued are those reporting no seizures for a long 
period, those with relatively few seizures before 
control was achieved, those taking a single 
antiepileptic drug, and those with a normal 
neurological examination with no structural brain 
lesion98. The role of the EEG in predicting 
seizure recurrence is somewhat more 
controversialWV9*. Some studies have indicated a 
low predictive value for this investigation, 
whereas others have suggested a better prognosis 
for continued remission when the EEG is normal. 
There are no protocols defining optimal regimens 
for tapering medication. Most specialists advise 
slow reduction over periods ranging from 2 to 6 
months. If the patient is taking antiepileptic 
polypharmacy, one drug should be completely 
withdrawn before the second is tapered. More 
than 90% of recurrences will occur during the 1st 
year following withdrawal, and most will present 
during the taper period or shortly after. 
EPILEPSY PROPHYLAXIS 
Some individuals are known to be at high risk of 
developing epilepsy. These include those with 
severe head trauma, significant central nervous 
system infection, supratentorial brain tumour, 
ventricular shunt, arteriovenous malformation, 
haemorrhagic stroke, etc. There are few data 
exploring the efficacy of antiepileptic drugs in 
preventing its development. One controlled trial 
showed that PHT could suppress seizures acutely 
after head injury99, but another did notIm. There 
is doubt, too, regarding their efficacy in prevent- 
ing the development of chronic epilepsy10’*‘02. 
Other trials have suggested that high serum 
antiepileptic drug concentrations are needed for 
successful prophylaxis’03. At the present time, it is 
difficult to recommend prophylactic antiepileptic 
treatment, but more research is needed in this 
important area. 
REFERRAL TO AN EPILEPSY CENTRE 
Some individuals with uncomplicated epilepsy are 
cared for by family practitioners, general physici- 
ans or pediatricians. However, as proper diag- 
nosis, accurate seizure and epilepsy syndrome 
classification, and appropriate selection and super- 
vision of medication is essential for optimal 
management, is is often in the patient’s best 
interests to involve a neurologist or other epilepsy 
specialist early in the evaluation. Patients with 
complicated seizure problems are more appropri- 
ately cared for by an epileptologist, who can 
provide additional expertise in diagnosis and 
treatment. 
If patients continue to have seizures, not clearly 
due to erratic compliance with medication, 
referral to an epilepsy centre can be essential for 
a number of reasons. Firstly, it appears that the 
more seizures an individual experiences, the more 
difficult they are to control. That ‘seizures (may) 
beget seizures’ has been hypothesized for more 
than 100 years’03. Thus, tolerating prolonged 
periods of uncontrolled seizures may be prognos- 
tically deleterious. Secondly, seizure classification 
may be hard to determine based on untrained 
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witness accounts. Video-EEG monitoring can 
provide a definitive diagnosis and classification, 
which can lead to more effective therapy. Some 
patients with ‘uncontrolled seizures’ are really 
having pseudoseizures, which are better treated 
by psychotherapy and, often, reduction in or 
withdrawal of antiepileptic medication. Thirdly, 
patients with uncontrolled seizures often receive 
polypharmacy and this may produce significant 
toxicity, which can be reduced by careful phar- 
macological simplification under monitored 
conditions’“4. Fourthly, patients who have failed 
to respond adequately to the standard drugs will 
have the opportunity to try one or more newer 
agents under carefully controlled conditions at an 
epilepsy centre. Lastly, appropriate decisions 
about surgery can best be made in a specialized 
centre. 
CONCLUSIONS 
In this paper, we have attempted an overview of 
the practical management of epilepsy using 
established antiepileptic drugs. When prescribing 
these agents, the following 12 basic rules should 
be followed: 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
Ensure that the diagnosis of epilepsy is 
soundly based, that there is no other under- 
lying correctable condition, and that the 
patient understands and accepts the necessity 
of taking antiepileptic drug therapy for some 
years; 
Choose the best drug for each individual 
patient using the international classifications 
of seizure types and epilepsy syndromes; 
Start at low dosage and titrate upwards in 
increments to a maintenance amount that 
controls the seizures but permits tolerance 
to central nervous system side-effects and 
avoids concentration-dependent toxicity; 
Keep the regimen simple with once or 
twice-daily dosing when possible; 
Counsel the patient early regarding the 
implications of the diagnosis, the prophylac- 
tic nature of the therapy, and the importance 
of perfect compliance; 
In patients proving resistant to a first-line 
drug but not complaining of side-effects, 
titrate the dose to the limit of tolerability 
without worrying about the circulating 
concentration: 
As monotherapy is the preferred approach 
for the majority of patients, a second drug 
should usually be substituted before embark- 
ing upon dual therapy; 
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8. It may more logical to add in a new drug with 
a potentially complementary mechanism of 
action than to combine established agents; 
9. Simplify dosage schedules and drug regimens 
as much as possible in patients who are truly 
refractory to antiepileptic polypharmacy; 
10. In refractory epilepsy, aim for the best 
seizure control consistent with optimal qual- 
ity of life; 
11. Refer patients to an epilepsy centre when 
seizures persist despite treatment with first- 
line drugs or in patients with problems 
tolerating the established agents; 
12. Consider epilepsy surgery early for patients 
with drug-resistant partial seizures or gene- 
ralized seizures with multiple falls. 
Good communication with the patient and his or 
her family, together with simple, clear and 
sympathetic explanations of the treatment plan 
and potential pitfalls, is essential throughout. 
Counselling about the implications of the diag- 
nosis is an important part of optimal 
management. 
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